Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo-Reference-Cited by-同舟云学术

Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo

Published:2019-07 Issue:7 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zhang Ye¹,Zhu Hui¹,Fu Lei¹,Wang Bin¹,Guo Shaochen¹,Chen Xi¹,Liu Zhongquan¹,Huang Haihong²,Yang Tianjian³,Lu Yu¹

Affiliation:

1. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China

2. Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

3. Global Alliance for TB Drug Development, New York, New York, USA

Abstract

TBI-166, derived from riminophenazine analogues, is under development in a phase I clinical trial in China. TBI-166 showed more potent anti-tuberculosis (anti-TB) activity than did clofazimine in in vitro and animal experiments.

Funder

National Science and Technology Project of China

Beijing Municipal Administration of Hospitals' Ascent Plan

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02496-18

Reference23 articles.

1. World Health Organization. 2017. Global tuberculosis report 2017. World Health Organization, Geneva, Switzerland.

2. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses